Last reviewed · How we verify
clexane (LMWH)
Clexane (enoxaparin) is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Clexane (enoxaparin) is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.
At a glance
| Generic name | clexane (LMWH) |
|---|---|
| Sponsor | HaEmek Medical Center, Israel |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Coagulation factors Xa and IIa (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, a natural anticoagulant. This results in selective inhibition of coagulation factors Xa and IIa, preventing thrombin generation and fibrin clot formation. It has a more predictable pharmacokinetic profile and longer half-life than unfractionated heparin, allowing for subcutaneous dosing.
Approved indications
- Thromboembolism prophylaxis in surgical patients
- Treatment of deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome
- Prevention of clotting in hemodialysis
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
Key clinical trials
- Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (PHASE4)
- Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
- Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction (NA)
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (PHASE3)
- A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (PHASE2)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis (PHASE3)
- Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clexane (LMWH) CI brief — competitive landscape report
- clexane (LMWH) updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI